MXPA06012232A - Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies. - Google Patents

Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies.

Info

Publication number
MXPA06012232A
MXPA06012232A MXPA06012232A MXPA06012232A MXPA06012232A MX PA06012232 A MXPA06012232 A MX PA06012232A MX PA06012232 A MXPA06012232 A MX PA06012232A MX PA06012232 A MXPA06012232 A MX PA06012232A MX PA06012232 A MXPA06012232 A MX PA06012232A
Authority
MX
Mexico
Prior art keywords
therapy
prediction
diagnosis
protein
plasma
Prior art date
Application number
MXPA06012232A
Other languages
Spanish (es)
Inventor
Maher Albitar
Elihu H Estey
Hagop M Kantarjian
Francis J Giles
Michael J Keating
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MXPA06012232A publication Critical patent/MXPA06012232A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25625—Dilution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
MXPA06012232A 2004-04-20 2005-04-20 Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies. MXPA06012232A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56387304P 2004-04-20 2004-04-20
PCT/US2005/013224 WO2005103719A2 (en) 2004-04-20 2005-04-20 Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies

Publications (1)

Publication Number Publication Date
MXPA06012232A true MXPA06012232A (en) 2007-06-15

Family

ID=35094386

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06012232A MXPA06012232A (en) 2004-04-20 2005-04-20 Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies.

Country Status (7)

Country Link
US (3) US7622306B2 (en)
EP (2) EP2221618A3 (en)
JP (1) JP4864875B2 (en)
BR (1) BRPI0509978A (en)
CA (1) CA2563847A1 (en)
MX (1) MXPA06012232A (en)
WO (1) WO2005103719A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756554A4 (en) * 2004-06-03 2009-04-29 Vermillion Inc Biomarkers for peripheral artery disease
US20070042443A1 (en) 2005-08-17 2007-02-22 Quest Diagnostics Investments Incorporated Hematopoietic cell phenotyping using free circulating cellular markers
JP2007240326A (en) * 2006-03-08 2007-09-20 Intec Web & Genome Informatics Corp Waveform analysis device
US20100140465A1 (en) * 2006-03-29 2010-06-10 Chulso Moon Apparatus and Method for Filtration to Enhance the Detection of Peaks
EP2109688A4 (en) * 2007-01-23 2010-02-17 Univ Virginia Galectin-3-binding protein as a biomarker of cardiovascular disease
US20120003744A1 (en) * 2007-08-14 2012-01-05 Petscreen Limited Diagnostic methods
KR100937720B1 (en) * 2009-04-20 2010-01-20 전남대학교산학협력단 A method for measurement of complement factor h (cfh) or apolipoprotein h (apoh) in serum of patients with acute myeloid leukemia to provide useful information in determining whether patients have achieved complete remission or not
KR101997543B1 (en) 2010-07-30 2019-07-09 이엠디 밀리포어 코포레이션 Chromatogrphy media and method
ES2877563T3 (en) 2014-09-02 2021-11-17 Emd Millipore Corp Chromotography media comprising discrete porous arrays of nanofibrils
CA2966515C (en) 2014-12-08 2021-04-27 Emd Millipore Corporation Mixed bed ion exchange adsorber
CN109507347B (en) * 2017-09-14 2021-01-29 湖南中烟工业有限责任公司 Chromatographic peak selection method
US11096582B2 (en) * 2018-11-20 2021-08-24 Veris Health Inc. Vascular access devices, systems, and methods for monitoring patient health
CN110632191B (en) * 2019-09-10 2023-04-18 福建工程学院 Transformer chromatographic peak qualitative method and system based on decision tree algorithm
EP4198511A1 (en) * 2021-12-17 2023-06-21 Lehtio, Janne Method for determining aml prognosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534121A (en) 1994-05-16 1996-07-09 The United States Of America As Represented By The Department Of Health And Human Services Preparative two dimensional gel electrophoresis system
EP1117992A1 (en) 1998-08-31 2001-07-25 C.B.S. Scientific Co., Inc. Two dimensional gel electrophoresis system
IN191209B (en) 1999-09-08 2003-10-04 Council Scient Ind Res
WO2002006829A2 (en) * 2000-07-18 2002-01-24 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
AUPQ886100A0 (en) * 2000-07-19 2000-08-10 Biotron Limited Diagnostic test
US20030013120A1 (en) 2001-07-12 2003-01-16 Patz Edward F. System and method for differential protein expression and a diagnostic biomarker discovery system and method using same
CA2485970A1 (en) * 2002-05-17 2004-04-08 Eastern Virginia Medical School Methods for diagnosing htlv-i-mediated diseases

Also Published As

Publication number Publication date
JP2007533997A (en) 2007-11-22
US20060073527A1 (en) 2006-04-06
EP2221618A3 (en) 2010-09-01
US8097468B2 (en) 2012-01-17
BRPI0509978A (en) 2007-10-16
CA2563847A1 (en) 2005-11-03
US20120145891A1 (en) 2012-06-14
US20100063747A1 (en) 2010-03-11
WO2005103719A2 (en) 2005-11-03
US7622306B2 (en) 2009-11-24
EP1756578A2 (en) 2007-02-28
US8563323B2 (en) 2013-10-22
JP4864875B2 (en) 2012-02-01
WO2005103719A3 (en) 2005-12-15
EP2221618A2 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
Kiddle et al. Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study
Russell et al. Protein Z: A putative novel biomarker for early detection of ovarian cancer
MXPA06012232A (en) Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies.
Zhang et al. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient
Srinivasan et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis
Drake et al. Serum, salivary and tissue proteomics for discovery of biomarkers for head and neck cancers
SG170061A1 (en) Biomarkers useful for diagnosing prostate cancer, and methods thereof
ATE490465T1 (en) DIAGNOSIS AND PROGNOSIS METHODS OF BLADDER CANCER.
WO2005083440A3 (en) Identification of cancer protein biomarkers using proteomic techniques
IL182062A0 (en) Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
Florentinus et al. Identification and quantification of peptides and proteins secreted from prostate epithelial cells by unbiased liquid chromatography tandem mass spectrometry using goodness of fit and analysis of variance
US9885085B2 (en) Apparatus, compositions, and methods for assessment of chronic obstructive pulmonary disease progression among rapid and slow decline conditions
WO2007016367A3 (en) Neoplastic disease-related methods, kits, systems and databases
HK1118337A1 (en) Methods for altering one or more parameters of a measurement system
WO2008048508A3 (en) Prognostic biomarkers in patients with ovarian cancer
WO2005010492A3 (en) Classification of disease states using mass spectrometry data
Siciliano et al. Rapid peptidomic profiling of peritoneal fluid by MALDI-TOF mass spectrometry for the identification of biomarkers of endometriosis
ATE370414T1 (en) USE OF NICOTINAMIDE N-METHYLTRANSFERASE FOR DIAGNOSING COLORECTAL CANCER
Gonzalez Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived?
WO2007126901A3 (en) Apparatus and method for predicting disease
AU2013262727A1 (en) SRM/MRM assay for subtyping lung histology
Matharoo-Ball et al. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches—a prostate cancer perspective
TW200613734A (en) Detection and identification of peptide and protein modifications
WO2006002240A8 (en) Computer systems and methods for constructing biological classifiers and uses thereof
Matharoo‐Ball et al. Serum biomarker profiling in cancer studies: a question of standardisation?